IsomAb
, IsomAb is developing a novel therapeutic approach to treating cardiovascular disease, with an initial focus on chronic stable angina (CSA) and peripheral arterial disease (PAD).
Developing isoform specific antibodies to treat disease
Faculty of Medicine and Health Sciences
Profile
Founded in 2022 as a spin-out from the University of Nottingham’s Faculty of Medicine and Health Sciences, IsomAb is developing a novel therapeutic approach to treating cardiovascular disease, with an initial focus on chronic stable angina (CSA) and peripheral arterial disease (PAD).
Cardiovascular disease is the leading cause of death worldwide, affecting more than 600 million people. Many patients experience insufficient blood flow to vital tissues due to partially blocked arteries and a lack of alternative blood vessels, limiting the body’s ability to deliver oxygen where it is needed most.
IsomAb’s lead therapeutic antibody, ISM-001, enhances the body’s natural ability to create a biological bypass by stimulating the growth of new blood vessels. In CSA, this approach generates a stronger blood vessel network, allowing blood to reach the heart quickly enough to support normal function, relieve pain during exercise, and reduce the risk of subsequent heart attacks. In PAD, ISM-001 promotes blood vessel growth in areas deprived of oxygen, enabling faster ulcer healing, reducing pain at rest, and improving mobility.